Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

NCT02992301 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerosis
Hyperlipidemia

Interventions

DRUG: Alirocumab

Sponsor

Westside Medical Associates of Los Angeles

Collaborators

[object Object]
[object Object]